U.S. markets open in 8 minutes
  • S&P Futures

    3,853.00
    +43.75 (+1.15%)
     
  • Dow Futures

    31,267.00
    +355.00 (+1.15%)
     
  • Nasdaq Futures

    13,076.00
    +165.00 (+1.28%)
     
  • Russell 2000 Futures

    2,240.30
    +41.10 (+1.87%)
     
  • Crude Oil

    61.74
    +0.24 (+0.39%)
     
  • Gold

    1,736.90
    +8.10 (+0.47%)
     
  • Silver

    27.01
    +0.57 (+2.17%)
     
  • EUR/USD

    1.2055
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.4360
    -0.0240 (-1.64%)
     
  • Vix

    24.84
    -4.05 (-14.02%)
     
  • GBP/USD

    1.3942
    +0.0020 (+0.14%)
     
  • USD/JPY

    106.5880
    +0.0860 (+0.08%)
     
  • BTC-USD

    48,021.04
    +3,251.70 (+7.26%)
     
  • CMC Crypto 200

    963.42
    +30.28 (+3.25%)
     
  • FTSE 100

    6,557.84
    +74.41 (+1.15%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually:

  • Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 pm ET

  • H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am ET

  • Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 1:15 pm ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005748/en/

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340

Josh Brodsky
(Investors)
617-551-8276